Multimmune

Multimmune is a German biotech pioneer in the theranostics space, built on a foundational discovery of membrane Hsp70 as a pan-cancer biomarker. The company's proprietary platform aims to develop both diagnostics and therapeutics targeting this marker, applicable across approximately 50-75% of cancers, including many solid tumors and hematological malignancies. As a private, clinical-stage entity, its strategy centers on creating a single, broad-spectrum approach to cancer treatment and imaging, positioning it within the precision medicine paradigm. The technology holds particular promise for targeting metastatic disease, which expresses even higher levels of the target.

Proprietary platform based on membrane-bound heat shock protein 70 (Hsp70) as a tumor-specific marker, expressed on ~50-75% of cancers (including many solid tumors and hematological malignancies) but not on healthy cells. Enables development of theranostics (combined diagnostic and therapeutic agents), drug targeting, and imaging tools.

Multimmune operates in the highly competitive oncology theranostics space. It faces competition from both large pharma companies with broad oncology portfolios and smaller biotechs developing targeted therapies and companion diagnostics. Its unique differentiator is the pursuit of a single, broad-spectrum biological target (membrane Hsp70) rather than mutations specific to cancer subtypes.